US drugmaker AbbVie has agreed to buy Allergan, the Irish-domiciled maker of Botox, in a US$63 billion that is the sector’s latest blockbuster transaction driven by the need to replenish drug pipelines.
AbbVie is betting the acquisition will improve its offering as Humira, the world’s best-selling treatment for inflammatory diseases, is set to face competition from generic versions as the drug goes off patent in the US.
Allergan’s portfolio is best known for Botox—a wildly popular non-surgical cosmetic treatment—but the company also makes drugs that are used in eyecare, gastroenterology, and to treat the central nervous system.
The deal, worth about US$80 billion including debt, is the second this year that would knit together two of the world’s biggest pharmaceutical companies. Earlier this year, Bristol-Myers Squibb agreed to pay US$74 billion for rival cancer drugmaker Celgene.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hogan Lovells Strengthens Antitrust Practice with Hire of Former FTC Official
Oct 16, 2024 by
CPI
DOJ Raises Antitrust Concerns Over Competitor-Only Data Sharing
Oct 15, 2024 by
CPI
Owens & Minor Faces Federal Inquiry Over Planned Acquisition of Rotech Healthcare
Oct 15, 2024 by
CPI
Brazil Poised to Regulate Stablecoins and Tokenized Assets by 2025, Says Central Bank Chief
Oct 15, 2024 by
CPI
Supreme Court Rejects Uber, Postmates Appeal on California’s Gig Worker Law
Oct 15, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh